Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.
Arsenne MekinianLucie BiardLorenzo DagnaPavel I NovikovCarlo SalvaraniOlivier EspitiaSavino SciasciaMartin MichaudMarc LambertJosé Hernández-RodríguezNicolas SchleinitzAbid AwisatXavier PuechalAchille AoubaHelene Munoz PonsIlya SmitienkoJean Baptiste GaultierLe Mouel EdwigeYgal BenhamouAntoinette PerlatPatrick JegoTiphaine GoulenokKarim SacreBertrand LiogerNolan HassoldJonathan BronerVirginie DufrostDaniel LevyJulie SeguierFrancois MaurierSabine BerthierAlexandre BelotFaten FrikhaGuillaume DenisAlexandra Audemard-VergerIsabelle Kone-PautSebastien HumbertPascal Woaye-HuneAlessandro TomelleriElena Marina BaldisseraMasataka KuwanaAlberto LogulloVahan MukuchyanAzeddine DellalFrancis GachesPierre ZeminskyElena GalliMoya AlvaradoLuigi BoiardiFrancesco MuratoreMathieu VautierCampochiaro CorradoSergey MoiseevMatheus VieiraPatrice CacoubOlivier FainDavid Saadounnull nullPublished in: RMD open (2023)
In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months.